Intravenous immunoglobulins (IVIGs) are widely used in the supportive therapy of immunodeficient patients and in the treatment of a wide variety of chronic autoimmune and inflammatory diseases.[1][1] [2][2] The proposed mechanisms of action of IVIG in these diseases include the inhibition of
No takes yet. Share an insight, caveat, or question.
Lamoureux et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: